Expert Interview
Discussing the commercial use of Vyjuvek in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and how Zevaskyn from Abeona may fit into the treatment algorithm
Ticker(s): KRYS, ABEOInstitution: Stanford University
- Clinical professor of Dermatology and Pediatrics at the Department of Dermatology at Stanford and Chief of Pediatric Dermatology.
- Currently treats 4-6 RDEB patients each month.
- Dr. Teng is an active physician scientist with strong interest and expertise in clinical and translational research especially in the area of rare genetic disorders. She is experienced in drug repurposing and trans-epidermal drug delivery and directs multidisciplinary care of patients with complex dermatologic conditions, genetic skin disease and vascular anomalies.
How many RDEB patients do you manage?
Added By: wilson_adminPlease describe your usage patterns with Vyjuvek
Added By: wilson_adminHow have you started using Zevaskyn in your practice?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
